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Here, we report the case of an HIV infected patient that was treated for pneumonia with a macrolid antibiotic. The patient
experienced a prolongation of the already pathologic QTc interval resulting in repeated torsades de pointes necessitating CPR
and implantation of an AICD. This case exempliﬁes that torsades de pointes due to acquired long QT syndrome is a serious and
potentially fatal complication in HIV-positive patients.
Human immunodeﬁciency virus- (HIV-) infected individ-
uals are at an increased risk of cardiovascular disease [1,
2]. Here, we report the case of an HIV-infected patient
with acquired long QT syndrome and multiple episodes
of torsades de pointes necessitating repeated cardiopul-
monary resuscitation. A 41-year-old HIV-positive patient
presented with dyspnea, cough, and fever to our emergency
department. The patient had just returned from a two-
week vacation to Egypt. In 1997, he was diagnosed with
HIV and an antiretroviral therapy (ART) was started. The
patient discontinued the ART in 2004 and at the time
of admission he was not taking any medications. He,
furthermore, complained of HIV-associated neuropathy of
thehandsandfeet.ChestX-rayrevealedbilateralinﬁltrates,a
diagnosis of bacterial pneumonia was made and an inpatient
treatment with ceftriaxone and clarithromycin was initiated
(CD4 count 0.06x1E9/l).
Two days after admission the patient experienced a
syncope. Since there was no palpable pulse, cardiopul-
monary resuscitation was performed by the medical team
for about 30 seconds after which the patient had regained
consciousness. The patient was transferred to the medical
intensive care unit for further observation. There was
no prior history of syncope, seizures, or cardiac events.
The 12-lead electrocardiogram showed QT prolongation
with a corrected QT interval (QTc, Bazett’s correction) of
660ms. In the following hours the patient had repeated
episodes of polymorphic ventricular tachycardias that were
either self-limiting or required deﬁbrillation. Figure 1 shows
representative ECGs recorded during some of these episodes.
Between the episodes, the patient’s ECG was characterized
by bradyarrhythmia with intermittent complex ventricular
prematurecomplexeswithburstsofcouplets(Figure 1(a)).A
premature ventricular beat (Figure 1(b)) precipitated poly-
morphic ventricular tachycardias with the typical electro-
cardiographic features of torsades de pointes (Figure 1(c)).
Following administration of mexiletine hydrochloride, no
further ventricular tachycardias occurred. Due to the high
likelihood of future treatment with QT-prolonging drugs
and the high risk of repeated events, the patient received
an automated implantable cardioverter deﬁbrillator (AICD).
During the follow-up no further cardiac events were
reported.
Long QT syndrome is more frequent in subjects infected
with HIV than in the general population and has been
reported to occur in up to 29% of the hospitalized HIV-
positive patients [2, 3]. Why long QT syndrome occurs more
often in HIV-positive patients is currently unknown. There2 Case Reports in Medicine
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Table 1
Antibiotics
Clarithromycin
Erythromycin
Pentamidine
Levoﬂoxacin
Moxiﬂoxacin
Ciproﬂoxacin
Cotrimoxazole (trimethoprim-sulfamethoxazole)
Antifungals
Voriconazole
Fluconazole
Itraconazole
Antiretrovirals
Atazanavir
Efavirenz
are multiple possible explanations why long QT syndrome
is more prevalent in HIV-infected patients, though. HIV-
positive patients frequently receive medications that prolong
the QT interval such as diﬂucan, clarithomycin, and cotri-
moxazol. Furthermore, antiretroviral drugs themselves have
been implied to cause prolongation of the QT interval [4–
6]. Table 1 summarizes drugs that are frequently given to
patients with HIV and that are thought to be associated with
QT prolongation. Whether HIV infection itself might cause
heart disease and QT-interval prolongation is controversial.
Inourpatient,medicationsalonedonotexplainthepresence
oflongQTsyndromesincereviewoftheECGobtainedupon
admission already showed prolongation of the QT interval
with a QTc of 474msec. Thus, other mechanisms must
have contributed to the prolongation of the QT interval.
Autonomic dysfunction due to HIV-associated neuropathy
is another presumed cause of long QT syndrome in HIV
patients and could have been a contributing factor in
our patient, who suﬀered from HIV-associated peripheral
neuropathy [7, 8].
This case exempliﬁes that torsades de pointes due to
acquired long QT syndrome is a serious and potentially
fatal complication in HIV-positive patients. Multiple factors
including antimicrobial drugs put HIV-infected patients at
an increased risk for the development of acquired long QT
syndrome. Physicians should therefore always maintain a
high degree of clinical suspicion for the presence of long QT
syndrome in patients with HIV and should be aware of the
QT-prolonging side eﬀects of drugs they prescribe for these
patients.
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